APPLICATION OF NANOPARTICLES BASED ON RARE EARTH ORTHOVANADATES TO INACTIVATE EHRLICH CARCINOMA GROWTH

The research of the peculiarities of Ehrlich carcinoma growth in vivo after incubation with nanoparticles based on rare-earth orthovanadates of spherical, spindle-like and rod-like shapes under different concentrations was the aim of this study. By immune fluorescence method there were quantitativel...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Biotechnologia acta 2015-08, Vol.8 (4), p.113-121
Hauptverfasser: Goltsev, A N, Babenko, N N, Gaevskaya, Yu A, Chelombitko, O V, Dubrava, T G, Bondarovich, N A, Ostankov, M V, Klochkov, V K, Kavok, N S, Malyukin, Yu V, Vinnik, Yu A
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The research of the peculiarities of Ehrlich carcinoma growth in vivo after incubation with nanoparticles based on rare-earth orthovanadates of spherical, spindle-like and rod-like shapes under different concentrations was the aim of this study. By immune fluorescence method there were quantitatively assessed the tumor precursors of various differentiation rate on the presence of phenotype markers CD44, CD24, CD 117 and Sca-1. The inhibition of tumor process after pre-treatment of Ehrlich carcinoma cells with nanoparticles of all the shapes and concentrations has been demonstrated. Nano-spindles of 0.875 g/l concentration were in a greater extent capable of tumor growth inhibiting that stipulates a maximal survival of tumor-bearing mice. There has been shown a significant redistribution in growing tumor of the content of the precursors with the mentioned above phenotype markers after pre-treatment of inoculated Ehrlich carcinoma cells with nanoparticles of all the shapes and concentrations. Predictive value of the coefficient of CD44^sup hi^ to CD117+ cells' ratio when assessing the anti-tumor therapy was found.
ISSN:2410-7751
1995-5537
2410-776X
DOI:10.15407/biotech8.04.113